GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Xilio Therapeutics Inc.
Xilio Therapeutics is a biotech company focused on developing tumor-activated oncology drugs. Its stock price represents a venture bet on the success of its scientific platform. The stock price reflects high volatility and dependence on clinical trial data.
Share prices of companies in the market segment - Cancer cure
Xilio Therapeutics is an oncology company developing immunotherapy drugs that are activated only in tumors to improve safety. We have classified the company in the "Cancer Treatment" category. The chart below shows how the market views geolocalized drug activation technologies.
Broad Market Index - GURU.Markets
Xilio Therapeutics is an oncology company developing immunotherapy drugs that are activated only in tumors to improve safety. As a component of the GURU.Markets index, it represents geolocalized drug activation technologies. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
XLO - Daily change in the company's share price Xilio Therapeutics Inc.
Xilio Therapeutics, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its immuno-oncology drugs.
Daily change in the price of a set of shares in a market segment - Cancer cure
Xilio Therapeutics, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with XLO's clinical trial-driven performance helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Xilio Therapeutics is a biotech company developing tumor-activated immuno-oncology drugs. Its shares are a bet on scientific breakthroughs. Their high volatility, driven by research results, contributes to the dynamics of the entire innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Xilio Therapeutics Inc.
Xilio Therapeutics' year-to-date performance is a story about developing "smart" cytokines that are activated only in tumors. Its 12-month market cap is entirely dependent on early clinical trial data. Success in this approach could lead to safer and more effective immunotherapy, the Holy Grail in this field.
Annual dynamics of market capitalization of the market segment - Cancer cure
Xilio Therapeutics, Inc. is a biotech company developing tumor-activated immunotherapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high potential of its scientific platform and the significant risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xilio Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Xilio Therapeutics Inc.
Xilio Therapeutics is an oncology company developing conditionally activated immunotherapy drugs. Its monthly performance is driven by news from its clinical programs. Data from trials of its targeted therapies is the primary factor influencing its valuation.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Xilio Therapeutics develops "smart" cancer immunotherapies that are activated only within the tumor to reduce side effects. This is a cutting-edge field in oncology. The chart below shows how investors assessed the prospects of this new generation of immuno-oncology drugs and whether they were willing to take risks for a potential breakthrough.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Xilio Therapeutics is an oncology company developing tumor-activated immunotherapy. It's another example of a high-tech biotech. Its stock price will be driven not by economic cycles, but by the stages of clinical trials and investor confidence in the company's scientific platform.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Xilio Therapeutics Inc.
Xilio Therapeutics is an oncology biotech. Its weekly stock price is a roller coaster, with every move driven by expectations and clinical trial results. Data releases can cause both a surge and a collapse, as is typical for this sector.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Xilio Therapeutics is an oncology biotech. Its weekly stock price is a roller coaster, with every move driven by expectations and clinical trial results. Data releases can cause both a surge and a collapse, as is typical for this sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Xilio, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
XLO - Market capitalization of the company Xilio Therapeutics Inc.
Xilio Therapeutics' market capitalization chart tells the story of the development of "smart" immuno-oncology, activated within tumors. Its dynamics reflect the hopes and risks associated with this technology, which promises to improve treatment efficacy and reduce side effects. It's a visualization of how the market values this cutting-edge, yet unproven, approach.
XLO - Share of the company's market capitalization Xilio Therapeutics Inc. within the market segment - Cancer cure
Xilio Therapeutics is a biotech company developing immuno-oncology drugs that are activated only in tumors to minimize side effects. Its share of its segment's market capitalization reflects the potential of this technology. The chart below shows how its weighting depends on clinical trial progress.
Market capitalization of the market segment - Cancer cure
Xilio Therapeutics develops immuno-oncology drugs that are activated only within the tumor to minimize side effects. The chart below shows the overall market capitalization of the oncology sector. It reflects the key challenge of modern therapy: increasing efficacy without sacrificing patient safety.
Market capitalization of all companies included in a broad market index - GURU.Markets
Another immuno-oncology strategy is shown here. Xilio Therapeutics creates drugs that are activated only in tumors to minimize side effects. Its volatile line on the chart reflects investors' belief that this "geo-targeted" approach will be the future of cancer treatment.
Book value capitalization of the company, segment and market as a whole
XLO - Book value capitalization of the company Xilio Therapeutics Inc.
Xilio Therapeutics' book value is determined by its scientific platform for developing "smart" immuno-oncology drugs that are activated only in tumors, and its financial reserves. This represents cutting-edge scientific capital. The chart shows how the company manages its budget for the development and clinical testing of next-generation anti-cancer therapies.
XLO - Share of the company's book capitalization Xilio Therapeutics Inc. within the market segment - Cancer cure
Xilio Therapeutics is a biotech company developing tumor-activated immuno-oncology drugs. Its assets are intellectual property. The chart shows the minimal share of physical assets, as it is an R&D company in the clinical stage.
Market segment balance sheet capitalization - Cancer cure
Immuno-oncology, as the BCap_Ges biotech chart shows, is a knowledge-intensive industry. Xilio Therapeutics operates in this environment, where its assets are its scientific platform and patents, not its manufacturing plants. It's a business where intellectual capital trumps physical capital.
Book value of all companies included in the broad market index - GURU.Markets
Xilio Therapeutics' book value represents capital invested in the development and patenting of tumor-activated oncology drugs. It reflects the financial foundation for the creation of "smart" physical drugs aimed at improving efficacy and reducing side effects.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Xilio Therapeutics Inc.
Xilio Therapeutics is another oncology company working on a technology for activating drugs inside tumors. Its MvsBCap story will be similar to BioAtla's. Market capitalization is not a valuation of assets, but a bet on a scientific hypothesis. The chart will be driven entirely by lab and clinical news, not financial reports.
Market to book capitalization ratio in a market segment - Cancer cure
Xilio Therapeutics is a biopharmaceutical company developing oncology drugs that activate directly in tumors. Its value lies in its proprietary technology. The chart reflects investor appreciation for its scientific approach, which aims to improve efficacy and reduce side effects.
Market to book capitalization ratio for the market as a whole
Xilio Therapeutics creates immuno-oncology drugs that are activated directly by tumors. This increases their effectiveness and reduces side effects. The company's value lies in this technology. The chart demonstrates the premium investors pay for intelligent approaches to cancer treatment based on a deep understanding of biology.
Debts of the company, segment and market as a whole
XLO - Company debts Xilio Therapeutics Inc.
Xilio Therapeutics, an oncology company developing "smart" drugs that activate only in tumors, is devoting all its capital to clinical trials. This innovative technology requires enormous R&D resources. This chart shows how the company is funding its research-intensive efforts to create safer and more effective immunotherapies.
Market segment debts - Cancer cure
Xilio Therapeutics is a biotech company developing immuno-oncology drugs that are activated only in tumors, potentially reducing side effects. Funding such an innovative, yet unproven, concept requires significant capital. The chart below reflects the company's financial strategy for the clinical trial stage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Xilio Therapeutics Inc.
Xilio Therapeutics, an oncology company developing a new generation of immunotherapy, shows its reliance on external funding to finance lengthy and expensive clinical trials. High debt is typical for biotech companies, but it also means the company's future is entirely dependent on scientific success.
Market segment debt to market segment book capitalization - Cancer cure
Xilio Therapeutics develops tumor-activated immuno-oncology drugs to improve their efficacy and safety. The chart shows the sector's debt burden. It helps understand how the company finances its expensive clinical trials and how its financial model compares to other innovative biotech companies.
Debt to book value of all companies in the market
Xilio Therapeutics is a biotech company developing tumor-selective immuno-oncology drugs. The chart below reflects the overall availability of capital in the market. For companies conducting expensive clinical trials, a favorable financial environment with moderate debt burden is key to attracting investment.
P/E of the company, segment and market as a whole
P/E - Xilio Therapeutics Inc.
For Xilio Therapeutics, another oncology company, this chart is a barometer of market expectations. High values or their volatility indicate that investors are assessing not current profits, but the potential of its drugs in clinical trials to become a new standard of cancer treatment.
P/E of the market segment - Cancer cure
This chart shows the average price-to-earnings ratio for the biotech sector, where Xilio Therapeutics develops oncology drugs. The industry's high valuation reflects expectations of future breakthroughs. The chart illustrates this general context, against which investors evaluate the scientific potential and risks associated with Xilio's developments.
P/E of the market as a whole
Xilio Therapeutics is developing a new generation of immuno-oncology drugs that are activated only within the tumor, which should minimize side effects. This chart illustrates the risk appetite in biotech. It helps understand how the market values this promising, yet unproven, technology and how its valuation compares to other companies working on smart cancer drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Xilio Therapeutics Inc.
Xilio Therapeutics is an oncology company developing immunotherapeutic drugs that are activated only in tumors to minimize side effects. This is cutting-edge research. This chart reflects analysts' confidence that the company's technology will be successful in clinical trials and find its niche in cancer treatment.
%20P%2FE%20Xilio%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Xilio-Therapeutics-Inc.&v=1772513773951 "Chart of the company's future (projected) P/E Xilio Therapeutics Inc.")
Future (projected) P/E of the market segment - Cancer cure
Xilio Therapeutics is developing a geo-targeted immuno-oncology therapy that is activated only within the tumor to minimize side effects. This chart shows analysts' estimates of the company's future revenue. Does the market believe its approach to localizing drug action will be a breakthrough in cancer treatment?
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772513773986 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Xilio Therapeutics is a biotech company developing a new generation of cancer immunotherapy. Its value lies in its future prospects. This chart, reflecting overall market sentiment, is an indicator of the availability of funding for such long-term projects. Investor optimism is oxygen for innovative companies like Xilio.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513774001 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Xilio Therapeutics Inc.
Xilio Therapeutics, Inc. is another biotech company developing immuno-oncology drugs that are activated only in tumors. Profitability is a long-term goal, and current finances are R&D expenses. This chart illustrates the capital required to develop "smart" drugs aimed at improving the effectiveness of cancer treatments.
Profit of companies in the market segment - Cancer cure
Xilio Therapeutics is a biopharmaceutical company developing "geographically precise" immuno-oncology drugs that are activated only within tumors. The goal is to increase efficacy and reduce toxicity. This graph reflects the potential in the oncology sector, where finding a balance between the potency of the antitumor response and safety is a key challenge.
Overall market profit
Xilio Therapeutics is another oncology company working on developing "smart" drugs that are active only in tumors. Its survival and success depend on access to funding. This chart, illustrating the overall health of the economy, influences investor risk appetite, which affects the entire biotech sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Xilio Therapeutics Inc.
Xilio Therapeutics is an oncology company developing immunotherapy drugs that are activated only in tumors to maximize their effectiveness and minimize side effects. This chart is a summary of analyst forecasts, betting on the success of this geo-targeted technology in clinical trials.
%20profit%20of%20the%20company%20Xilio%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Xilio-Therapeutics-Inc.&v=1772513774075 "Graph of future (projected) profit of the company Xilio Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Xilio Therapeutics is a biotech company developing "smart" immuno-oncology drugs that are activated only within the tumor. This tumor-activated approach aims to maximize efficacy and minimize systemic side effects. This chart shows profitability projections for the biotech sector, reflecting expectations for the next generation of targeted cancer therapies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772513774079 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Xilio Therapeutics is another company working in the immuno-oncology field. Its success depends on clinical trial results and its ability to attract funding. This graph, by showing general profitability expectations, influences investor risk appetite and, consequently, the valuation and availability of capital for early-stage biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513774087 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Xilio Therapeutics Inc.
Xilio Therapeutics is a biotech company focused on oncology. This chart shows its estimated future potential. For a company with products in development, a high market value without sales reflects investor expectations for the success of its clinical programs.
P/S market segment - Cancer cure
Xilio Therapeutics, Inc. is a biopharmaceutical company developing immuno-oncology drugs that are activated only in tumors. This chart reflects the average revenue estimate in the biotech sector. It allows us to estimate the premium investors are placing on the potential of Xilio's technology to create safer and more effective cancer treatments.
P/S of the market as a whole
Xilio Therapeutics develops tumor-activated immunotherapy that releases its potency only within cancer cells, minimizing damage to healthy tissue. Their goal is to make treatment more effective and safer. This chart provides a general measure of revenue valuation, which can be used to assess how highly investors value the next generation of oncology drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Xilio Therapeutics Inc.
Xilio Therapeutics develops immuno-oncology drugs that are activated only within the tumor to minimize side effects. This chart illustrates investors' confidence in this "geo-targeted" technology. The company's valuation depends entirely on the success of clinical trials and the potential of its approach to transform cancer treatment.
%20P%2FS%20Xilio%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Xilio-Therapeutics-Inc.&v=1772513774171 "The graph of the company's future (projected) P/S Xilio Therapeutics Inc.")
Future (projected) P/S of the market segment - Cancer cure
Xilio Therapeutics is a biopharmaceutical company developing immuno-oncology drugs that are activated only in tumors. This approach aims to improve efficacy and reduce toxicity. This chart shows how the market values its "geographically restricted" therapy technology compared to the oncology sector.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772513774187 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Xilio Therapeutics is an oncology company developing drugs that are activated only within tumors to minimize side effects. This graph, reflecting the biotech investment climate, directly impacts Xilio. Investors' willingness to invest in long-term, risky projects, which increases during periods of optimism, is vital for funding the company's research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513774199 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Xilio Therapeutics Inc.
Xilio Therapeutics is a biotech company developing geo-targeted immuno-oncology therapies that are activated only within tumors. This chart reflects revenue from collaborations with other pharmaceutical companies. It illustrates the financial support for a cutting-edge approach aimed at increasing treatment efficacy while reducing side effects.
Sales of companies in the market segment - Cancer cure
Xilio Therapeutics, Inc. is a biotechnology company developing a new class of immuno-oncology therapies that are activated only in tumors to maximize efficacy and minimize side effects. Its business is segmented by various development programs. This chart depicts the financial flows associated with one of its key candidates.
Overall market sales
Xilio Therapeutics, Inc. is another biotech company developing immuno-oncology drugs that are activated only in tumor cells. The goal is to improve treatment efficacy and reduce toxicity. Like other companies in this sector, its value is determined by scientific potential, not current economic conditions.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Xilio Therapeutics Inc.
Xilio Therapeutics is a biotech company developing geo-targeted immuno-oncology therapies that are activated only within tumors. Future sales projections are based on the expected success of its clinical programs. This is a bet that its technology will enable the creation of more potent and safer cancer treatments.
%20sales%20of%20the%20company%20Xilio%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Xilio-Therapeutics-Inc.&v=1772513774257 "Schedule of future (projected) sales of the company Xilio Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Xilio Therapeutics is developing tumor-activated immunotherapy to improve treatment efficacy and reduce side effects. This graph reflects expectations for the entire oncology sector. It helps understand the potential analysts are predicting for smarter and safer drugs, which is key for the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772513774260 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Xilio Therapeutics, an oncology company developing next-generation immunotherapies, is funded by a combination of venture capital and the public market. This graph of overall sales forecasts reflects the economic confidence that drives investor risk appetite, which is essential to supporting biotech.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513774277 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Xilio Therapeutics Inc.
Xilio Therapeutics, Inc. is an oncology company developing a new class of immunotherapeutic drugs that are activated only within tumors to minimize side effects. This chart shows its financial trajectory through the R&D stage, where ongoing research expenditures are an investment in the creation of safer and more effective cancer drugs.
Market segment marginality - Cancer cure
Xilio Therapeutics is a biopharmaceutical company developing tumor-activated immuno-oncology drugs. Their goal is to improve therapy efficacy and reduce side effects, which can accelerate R&D. The chart demonstrates how competitive their operating model is in the complex and capital-intensive field of drug development.
Market marginality as a whole
Xilio Therapeutics, Inc. is a biotech company developing immuno-oncology drugs that are activated only in tumors. This maximizes their efficacy and minimizes damage to healthy tissue. This chart shows the profitability of established companies, but for Xilio, success depends on breakthrough technology and clinical trial results.
Employees in the company, segment and market as a whole
Number of employees in the company Xilio Therapeutics Inc.
Xilio Therapeutics is developing a new generation of anti-cancer immunotherapy that activates directly within the tumor. This graph shows its key asset—its team of scientists. The growth of this team is directly related to the volume of investment in research and the advancement of its "smart" drugs through the preclinical and clinical development stages.
Share of the company's employees Xilio Therapeutics Inc. within the market segment - Cancer cure
Xilio Therapeutics is another company working on developing tumor-activated anticancer drugs. This approach promises to reduce side effects. This figure reflects the company's commitment to developing smarter and safer cancer treatments.
Number of employees in the market segment - Cancer cure
Xilio Therapeutics is a biotech company developing immuno-oncology drugs that are activated only in tumors. This chart reflects the oncology sector. The growing number of researchers in the field of targeted therapy underscores the industry's commitment to minimizing treatment side effects, a key advantage of Xilio's technology.
Number of employees in the market as a whole
Xilio Therapeutics is an oncology company developing immunotherapy. Its growth depends on funding and clinical trial success. This chart shows the overall economic situation, but for Xilio, raising the next round of investment to continue hiring top scientists is far more important.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Xilio Therapeutics Inc. (XLO)
Xilio Therapeutics, Inc. develops tumor-activated immuno-oncology drugs. The high value on this chart indicates that the market is betting on this breakthrough technology. The company's entire value lies in its patents and the results of preclinical studies, which are being developed by a small team of scientists.
%20of%20the%20company%20Xilio%20Therapeutics%20Inc.%20(XLO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Xilio-Therapeutics-Inc.-XLO&v=1772513774482 "Chart of market capitalization per employee (in thousands of dollars) of the company Xilio Therapeutics Inc. (XLO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Xilio Therapeutics is a biotech company developing tumor-activated immunotherapy to minimize side effects. In this cutting-edge field, the company's cost per employee reflects how the market values its unique scientific platform. It's a measure of investors' faith in the team's ability to create safer and more effective cancer treatments.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772513774496 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Xilio Therapeutics, Inc. is another biotech company developing immuno-oncology drugs (cytokines) that are activated only in tumors. This approach promises to improve treatment efficacy and safety. The chart reflects how the market values this scientific approach aimed at targeted cancer treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513774526 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Xilio Therapeutics Inc. (XLO)
Xilio Therapeutics is another clinical-stage biopharmaceutical company specializing in "smart" immuno-oncology. Their drugs (cytokines and antibodies) are designed to be activated only in tumors. This negative graph shows how much capital is "burned" per scientist working on this complex R&D platform to create more effective and less toxic cancer treatments.
%20Chart%20Xilio%20Therapeutics%20Inc.%20(XLO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Xilio-Therapeutics-Inc.-XLO&v=1772513774532 "Company Profit Per Employee (in thousands of dollars) Chart Xilio Therapeutics Inc. (XLO)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Xilio Therapeutics is a biotech company developing tumor-selective immuno-oncology drugs. Their goal is to maximize treatment efficacy while minimizing side effects. This graph shows the value generated by their highly specialized team of scientists, allowing us to evaluate their productivity relative to the industry average.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772513774586 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Xilio Therapeutics (XLO) is another biotech R&D company working in the field of immuno-oncology. Like others, it has no commercial products. This negative metric reflects the cost of maintaining a top-notch scientific team. It shows investors the extent of their investment in personnel working on the development of future breakthrough drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513774632 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Xilio Therapeutics Inc. (XLO)
Xilio Therapeutics is another clinical-stage oncology company developing geo-targeted immunotherapy. Its revenue is likely nonexistent at this stage. This graph is an indicator of future potential, which will only be realized if clinical trials are successfully completed.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Xilio-Therapeutics-Inc.-XLO&v=1772513774696 "Sales chart per company employee Xilio Therapeutics Inc. (XLO)")
Sales per employee in the market segment - Cancer cure
Xilio Therapeutics is another oncology company developing "smart" immunotherapeutic drugs that are activated only in tumors. This chart compares revenue per employee (R&D) to the industry average, allowing one to assess the effectiveness of their scientific platform and the value of their developments for potential partners.
Sales per employee for the market as a whole
Xilio Therapeutics (XLO) is another clinical-stage biotech focused on immuno-oncology. They are also developing "smart" drugs that are activated by tumors. The company has no commercial sales revenue. This graph would show $0, which is typical for R&D companies whose research staff is focused on clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Xilio Therapeutics Inc. (XLO)
Xilio Therapeutics (XLO) is another oncology company also working on "geo-targeted" immunotherapy (activation only within the tumor). This chart shows the number of investors who are betting against this specific approach, considering it too complex or inferior to competitors' developments in this hot field.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Xilio-Therapeutics-Inc.-XLO&v=1772513774892 "Short Shares Chart for the Company Xilio Therapeutics Inc. (XLO)")
Shares shorted by market segment - Cancer cure
Xilio Therapeutics is another oncology company developing "geographically restricted" immunotherapies. Their drugs are activated only in the tumor to avoid systemic side effects. This chart shows the odds against the oncology biotech sector, reflecting the general market skepticism toward early-stage companies in this competitive field.
Shares shorted by the overall market
Xilio (XLO) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing XLO won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Xilio Therapeutics Inc. (XLO)
Xilio Therapeutics is another oncology company working on a "smart" immunotherapy that activates only in tumors. This chart measures investor sentiment in this competitive sector, showing when optimism about their platform (above 70) or pessimism (below 30) reaches extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Xilio-Therapeutics-Inc.-XLO&v=1772513774956 "RSI 14 indicator chart for the company's stock Xilio Therapeutics Inc. (XLO)")
RSI 14 Market Segment - Cancer cure
Xilio Therapeutics is an oncology company developing "geospatial-constrained" immunotherapies. Their drugs (cytokines and antibodies) are activated only within the tumor to increase efficacy and reduce side effects. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
For Xilio Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the cash spigot is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast XLO (Xilio Therapeutics Inc.)
Xilio Therapeutics is a biotech company developing tumor-activated immuno-oncology (IO), which activates only in tumors. This chart shows the average target price. Analysts' estimates are based on clinical data demonstrating the safety and efficacy of this approach.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-XLO-Xilio-Therapeutics-Inc.&v=1772513775034 "A chart showing analyst consensus forecasts for the expected stock price. XLO (Xilio Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price XLO (Xilio Therapeutics Inc.)
Xilio Therapeutics is an oncology company developing "geo-targeted" immunotherapy (cytokines) that activates only within tumors. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the price and the forecast, reflecting their faith in this "smart" and potentially safer technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-XLO-Xilio-Therapeutics-Inc.&v=1772513775076 "A chart showing the difference between the consensus forecast and the actual stock price. XLO (Xilio Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Xilio Therapeutics is a biotech company developing "geo-targeted" immunotherapy (cytokines) that is activated only within tumors (cloaking technology). This chart shows the general expectations of oncology analysts. It reflects whether experts believe in the success of "smart" drugs with fewer side effects.
Analysts' consensus forecast for the overall market share price
Xilio Therapeutics is a biotech company specializing in the development of geo-targeted immunotherapies (cytokines) that are activated only within tumors to avoid side effects. This chart shows the overall market "risk appetite." For Xilio, a high-risk clinical-stage company, overall market optimism is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Xilio Therapeutics Inc.
Xilio Therapeutics is smart oncology. Like BioAtla, they develop conditionally active (CAB) cytokines that remain dormant in the body but are activated only in tumors to avoid toxicity. This graph is a clear indicator of faith in their R&D. It reflects their progress in clinical trials and the market's confidence in their innovative cloaking platform.
AKIMA Market Segment Index - Cancer cure
Xilio Therapeutics (XLO) is another oncology company developing geographically restricted immunotherapies. Their drugs (cytokines, antibodies) are activated only within the tumor to maximize efficacy and minimize harm. The chart shows the segment's average index, helping investors assess how this in-situ activation strategy compares to the average.
The AKIM Index for the overall market
Xilio Therapeutics is an immuno-oncology company developing tumor-activated cytokines and antibodies. The goal is efficacy without systemic toxicity. This chart, which reflects the market average, provides a macro backdrop. It helps assess how Xilio, which is testing its hypotheses in the clinic, compares to overall economic trends.
